BeOne Medicines (SHA:688235, HKG:6160) posted first-half attributable net profit of 3.27 billion yuan, up 627% from 449.8 million yuan the previous year.
Basic earnings per share jumped to 2.26 yuan from 0.32 yuan, according to a Thursday filing with the Shanghai bourse.
Operating revenue climbed 27% year over year to 22.2 billion yuan from 17.5 billion yuan.
Shares of the oncology company fell 5% in recent trade on the Shanghai bourse.